Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 14.20 is 535% above its 5-year average of 2.23, around the middle of its 5-year range (0.00–20.93).
As of the fiscal period ended Tuesday, June 30, 2026. 81.85% above its 12-month average of 7.81.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 14.20.
QUICK RATIO (ACID-TEST)
14.20
QUICK RATIO (ACID-TEST) AVG TTM
7.81
QUICK RATIO (ACID-TEST) AVG 3Y
1.85
QUICK RATIO (ACID-TEST) AVG 5Y
2.23
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+81.85%
CURRENT VS 3Y AVG
+668.84%
CURRENT VS 5Y AVG
+535.37%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 568 covered companies
CURRENT VS SECTOR MEDIAN
+374.79%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$716.11M
Quick Ratio (Acid-Test)
14.20
TTM Avg
7.81
3Y Avg
1.85
5Y Avg
2.23
Market Cap
$715.49M
Quick Ratio (Acid-Test)
0.84
TTM Avg
1.18
3Y Avg
1.08
5Y Avg
1.08
Market Cap
$715.02M
Quick Ratio (Acid-Test)
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$719.62M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$740.03M
Quick Ratio (Acid-Test)
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$745.42M
Quick Ratio (Acid-Test)
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$683.14M
Quick Ratio (Acid-Test)
19.69
TTM Avg
6.38
3Y Avg
9.16
5Y Avg
11.87
Market Cap
$762.81M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.81
3Y Avg
5.95
5Y Avg
7.14
Market Cap
$764.21M
Quick Ratio (Acid-Test)
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $716.11M | 14.20 | 7.81 | 1.85 | 2.23 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.49M | 0.84 | 1.18 | 1.08 | 1.08 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $715.02M | 0.95 | 4.92 | 2.98 | 5.72 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.62M | 19.31 | 14.05 | 7.67 | 5.91 |
| Candel Therapeutics, Inc. (CADL)vs › | $740.03M | 16.09 | 8.04 | 7.87 | 9.13 |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | 18.86 | 23.23 | 26.78 | 32.61 |
| Faeth Therapeutics, Inc. (FTH)vs › | $683.14M | 19.69 | 6.38 | 9.16 | 11.87 |
| Cytek Biosciences, Inc. (CTKB)vs › | $762.81M | 3.86 | 4.81 | 5.95 | 7.14 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.21M | 9.39 | 11.79 | 11.79 | 11.79 |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 4.79 | 3.80 | 3.38 | 3.21 |
Quick Ratio
14.20
Excludes inventory
Current Ratio
14.20
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 14.20 |
| 2026-03-31 | 20.93 |
| 2025-12-31 | 0.73 |
| 2025-09-30 | 0.80 |
| 2025-06-30 | 2.38 |
| 2025-03-31 | 3.65 |
| 2024-12-31 | 4.48 |
| 2024-09-30 | 0.90 |
| 2024-06-30 | 0.88 |
| 2024-03-31 | 1.09 |
| 2023-12-31 | 2.51 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 2.88 |
| 2023-03-31 | 2.88 |
| 2022-12-31 | 2.33 |
| 2022-09-30 | 2.33 |
| 2022-06-30 | 4.25 |
| 2022-03-31 | 4.25 |
| 2021-12-31 | 1.94 |
| 2021-09-30 | 1.94 |
